Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

Investors

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.

Minimum 15 minutes delayed. Source: LSEG

Show all

Latest Results | Q3 2026

  • Earnings Release

Events

01 Dec 2026 10:00 AM AEDT
General Meeting of Shareholders
03 Nov 2026 from 5:00 PM to 8:00 PM EST
Capital Markets Day
22 Sep 2026 from 8:30 AM to 12:30 PM EDT
Telix 2026 R&D Day 2026 (New York City)
20 Sep 2026 7:30 PM EDT
Telix Pharmaceuticals Limited Investor Conference Call
15 Sep 2026 10:30 AM EDT
H.C. Wainwright 28th Annual Global Investment Conference
  • All Events

 

Presentations

Telix Capital Markets Day Presentation
  • All Presentations

News

05 Nov 2026
Appendix 3Y Maria Rivas
04 Nov 2026
Telix Capital Markets Day Presentation November 2026
03 Nov 2026
Change of Director's Interest Notice - Marie McDonald
03 Nov 2026
Notification regarding unquoted securities - TLX
03 Nov 2026
Cancellation of Appendix 2A
  • All News Releases

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors